Biomarkers and immune-modulating therapies for Type 2 diabetes

Trends in Immunology

Volumn 33, Issue 11, 2012, Pages 546-553

  Brooks Worrell, Barbara ^a,b   Narla, Radhika ^b,c   Palmer, Jerry P ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autoimmunity; Biomarkers; Immunomodulatory drugs; Immunotherapy; Inflammation; Obesity; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALBUMIN; ALEGLITAZAR; BIOLOGICAL MARKER; CANAKINUMAB; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ETANERCEPT; GEVOKIZUMAB; GLIBENCLAMIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INFLIXIMAB; LY 2189102; METFORMIN; OTELIXIZUMAB; PIOGLITAZONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RESOLVIN; RESVERATROL; RITUXIMAB; ROSIGLITAZONE; SALICYLIC ACID DERIVATIVE; SALSALATE; SULFONYLUREA; TEPLIZUMAB; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

AUTOIMMUNITY; DIABETIC PATIENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STOMACH ULCER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; AUTOIMMUNITY; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNOTHERAPY;

EID: 84867911343     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.07.002     Document Type: Review

References (91)

1. Ehses J.A., et al. Pancreatic islet inflammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch. Physiol. Biochem. 2009, 115:240-247.
2. Donath M.Y., et al. Islet inflammation in type 2 diabetes. Diabetes Care 2008, 31:S161-S164.
3. Donath M.Y., et al. Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology 2009, 24:325-331.
4. Kintscher U., et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1304-1310.
5. Nishimura S., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15:914-920.
6. Winer S., et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 2009, 15:921-929.
7. Wu H., et al. T-cell accumulation and regulation on activation, normal T cell expressed and secreted up-regulation in adipose tissue in obesity. Circulation 2007, 115:1029-1038.
8. Feuerer M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameter. Nat. Med. 2009, 15:930-940.
9. Deiuliis J., et al. Visceral adipose inflammation in obesity is associated with critical alterations in T regulatory cell numbers. PLoS ONE 2011, 6:e16376-e16387.
10. Lumeng C.N., et al. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 56:16-23.
11. Visser M., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
12. Calabro P., et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J. Am. Coll. Cardiol. 2005, 46:1112-1113.
13. Meijer K., et al. Human primary adipocytes exhibit immune cell function: Adipocytes prime inflammation independent of macrophages. PLoS ONE 2011, 6:e17154-e17167.
14. Ouchi N., et al. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
15. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
16. Spranger J., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 2003, 52:812-817.
17. Pradhan D.A., et al. C-reactive protein, interleukin-6 and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
18. Lindsay R.S., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57-58.
19. Hotamisligil G.S., et al. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
20. Ilan Y., et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. PNAS 2010, 107:9765-9770.
21. Cipolletta D., et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012, 486:549-553.
22. Yamauchi T., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 941-946.
23. Brooks-Worrell B., Palmer J.P. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin. Exp. Immunol. 2012, 167:40-46.
24. Brooks-Worrell B.M., et al. Cellular immune responses to human islet proteins in antibody positive type 2 diabetic patients. Diabetes 1999, 48:983-988.
25. Brooks-Worrell B.M., et al. Identification of autoantibody negative autoimmune type 2 diabetes patients. Diabetes Care 2011, 34:168-173.
26. Goel A., et al. T-Cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007, 56:2110-2115.
27. DeFronzo R.A., et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 2011, 364:1104-1115.
28. Stanley T.L., et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J. Clin. Endocrinol. Metab. 2011, 96:E146-E150.
29. Tak P.P., Kalden J.R. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011, 13(Suppl. 1):S5.
30. Roep Bo, et al. The problems and promises of research into human immunology and autoimmune disease. Nat. Med. 2012, 18:48-53.
31. Groop L., et al. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986, 35:237-241.
32. Zimmet P., et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabetes Med. 1994, 11:299-303.
33. Dinarello C.A. Blocking interleukin-1β in acute and chronic auto-inflammatory diseases. J. Intern. Med. 2011, 269:16-28.
34. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 17:3720-3732.
35. Dinarello C.A., et al. Role of IL-1β in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:314-321.
36. Larsen C.M., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Eng. J. Med. 2007, 356:1517-1526.
37. Larsen C.M., et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32:1663-1668.
38. Dominguez H., et al. Metabolic and vascular effects of tumor necrosis factor- alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 2005, 42:517-525.
39. Chawla A., et al. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994, 135:798-800.
40. Willson T.M., et al. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 2001, 70:341-347.
41. Kahn S.E., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006, 355:2427-2443.
42. Marx N., et al. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 2002, 90:703-710.
43. Clark R.B., et al. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J. Immunol. 2000, 164:1364-1371.
44. Giaginis C., et al. Peroxisome proliferator-activate receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. Pharmacol. Res. 2009, 60:160-169.
45. Foryst-Ludwig A., et al. PPAR-gamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc. Diabetol. 2010, 9:64-73.
46. Kleeman R., et al. Evidence for anti-inflammatory activity of statins and PPAR-alpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004, 103:4188-4194.
47. Leung B.P., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 2003, 170:1524-1530.
48. Rajpathak S.N., et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
49. Yin M.J., et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IkB kinase-β Nature 1998, 396:77-80.
50. Goldfine A.B., et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 2008, 1:36-43.
51. Goldfine A.B., et al. TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team: the effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 2010, 152:346-357.
52. Fleischman A., et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008, 31:289-294.
53. Pierce G.L., et al. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 2009, 119:1284-1292.
54. Hellmann J., et al. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 2011, 25:2399-2407.
55. Titos E., et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 2011, 187:5408-5418.
56. Farrat F.J., Coffman R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 2008, 223:271-283.
57. Wong F.S., Wen L. Toll-like receptors and diabetes. Ann. N. Y. Acad. Sci. 2008, 1150:123-132.
58. Fousteris E., et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc. Diabetol. 2011, 10:101-107.
59. Dasu M.R., et al. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010, 33:861-868.
60. Devaraj S., et al. Knockout of toll-like receptor-2 attenuates both the pro-inflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1796-1804.
61. Cole B.K., et al. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010, 55:715-721.
62. Faraco G., et al. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol. Med. 2011, 17:442-447.
63. Glauben R., Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol. Med. 2011, 17:426-433.
64. Nicodeme E., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
65. Lawless M.W., et al. Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders. Endocr. Metab. Immune Disord. Drug Targets 2009, 9:84-107.
66. Christensen D.P., et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med. 2011, 17:378-390.
67. Duez H., et al. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem. Pharmacol. 2012, 83:823-832.
68. Nauck M.A., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 2007, 9:194-205.
69. Kazantsev A.G., Outeiro T.F. Editorial on special topic: sirtuins in metabolism, aging, and disease. Front. Pharmacol. 2012, 3:71.
70. Jiang W.-J. Sirtuins. Novel targets for metabolic disease in drug development. Biochem. Biophys. Res. Commun. 2008, 373:341-344.
71. Cavender M.A., Lincoff A.M. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am. J. Cardiovasc. Drugs 2010, 10:209-216.
72. Henry R.R., et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135.
73. Kaufman A., Herold K.C. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab. Res. Rev. 2009, 25:302-306.
74. Waldron-Lynch F., Herold K.C. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat. Rev. 2011, 10:439-452.
75. Pescovitz M.D., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function for the Type 1 Diabetes TrialNet Anti-CD20 Study Group. N. Engl. J. Med. 2009, 361:2143-2152.
76. Herold K.C., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002, 346:1692-1698.
77. Winer D.A., et al. B cell promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011, 17:610-617.
78. Palmer J.P., et al. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age?. Diabetes 2005, 2:s62-s67.
79. Samaropoulos X.F., et al. The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Res. Clin. Pract. 2012, 95:389-398.
80. Aso Y., et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl. Res. 2012, 159:25-31.
81. Zampetaki A., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 2010, 107:810-817.
82. Bonora E., et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004, 53:1782-1789.
83. Seyfert-Margolis V., et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006, 55:2588-2594.
84. Herold K.C., et al. The type 1 diabetes TrailNet research group. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009, 58:2588-2595.
85. Brooks-Worrell B.M., et al. Peripheral blood mononuclear cells of insulin-dependent diabetic patients: respond to multiple islet cell proteins. J. Immunol. 1996, 157:5668-5674.
86. Brooks-Worrell B., et al. Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J. Clin. Endocrinol. Metab. 2004, 89:2222-2227.
87. Gilliam L.K., et al. Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes. J. Autoimmun. 2005, 25:244-250.
88. Brooks-Worrell B., et al. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J. Immunol. 2001, 166:5265-5270.
89. Mannering S.I., et al. Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes. Clin. Exp. Immunol. 2010, 162:197-209. on behalf of the immunology of Diabetes Society T cell Workshop Committee.
90. Fierabracci A. The potential of multimer technologies in type 1 diabetes prediction strategies. Diabetes Metab. Res. Rev. 2011, 27:216-229.
91. James E.A., et al. Immunology of Diabetes Society T cell workshop: HLA class II tetramer-directed epitope validation initiative. Diabetes Metab. Res. Rev. 2011, 27:727-736. T cell workshop Committee of the Immunology of Diabetes Society.